Which peripheral opioid antagonist is more effective, naloxegol or Relistor (methylnaltrexone)?

Naloxegol and Relistor (Methylnaltrexone) Have Similar Efficacy

Based on the 2019 AGA guidelines and recent comparative studies, naloxegol and methylnaltrexone (Relistor) demonstrate comparable effectiveness for opioid-induced constipation, but naloxegol has stronger evidence quality and is significantly more cost-effective. 1, 2

Evidence Quality and Recommendations

The 2019 AGA guidelines provide different strength recommendations for these agents:

• Naloxegol: Strong recommendation with moderate-quality evidence 1, 2
• Methylnaltrexone: Conditional recommendation with low-quality evidence 2

This difference in evidence quality is clinically meaningful—naloxegol has more robust trial data supporting its use, while methylnaltrexone's evidence base is weaker.

Head-to-Head Comparative Data

Recent direct comparison studies show:

Hospital Setting (2023): Naloxegol was noninferior to methylnaltrexone for achieving bowel movement within 48 hours (risk difference -4.6%, meeting the prespecified 15% noninferiority margin). Naloxegol cost $193.16 less per patient 3

ICU Setting (2024): Naloxegol was noninferior to methylnaltrexone with median time to first bowel movement of 23.7 hours vs 18.3 hours. Cost per bowel movement was dramatically different: $21.74 for naloxegol vs $170.00 for methylnaltrexone 4

Practical Clinical Considerations

Route of Administration

• Naloxegol: Oral only (25 mg daily)
• Methylnaltrexone: Both subcutaneous and oral formulations available 5

Choose methylnaltrexone when: Patient cannot take oral medications or has severe gastroparesis/ileus

Choose naloxegol when: Patient can take oral medications (which is most situations)

Onset of Action

Both agents work within 24-48 hours, with methylnaltrexone potentially slightly faster (18 vs 24 hours median) but this difference is not clinically significant for most patients 4

Cost Considerations

Naloxegol provides substantial cost savings—approximately 8-fold lower cost per bowel movement compared to methylnaltrexone 4. This makes naloxegol the preferred first-line PAMORA when oral administration is feasible.

Clinical Algorithm

For laxative-refractory OIC:

1. If patient can take oral medications → Start naloxegol 25 mg daily (stronger evidence, lower cost)

2. If patient cannot take oral medications → Use subcutaneous methylnaltrexone 8-12 mg based on weight 5

3. If naloxegol fails → Switch to methylnaltrexone (one case report demonstrates this rescue strategy works) 6

4. Adjust doses in renal/hepatic impairment per FDA labeling 5

Important Caveats

• Neither agent is definitively "stronger"—they work through the same mechanism (peripheral mu-opioid receptor antagonism)
• The main differences are evidence quality, cost, and route of administration—not efficacy
• Both agents can cause GI adverse effects (abdominal pain, diarrhea) at similar rates 1
• Neither agent reverses central analgesia when used at recommended doses 5

Bottom line: Use naloxegol as first-line for oral-capable patients due to stronger evidence and dramatically lower cost. Reserve methylnaltrexone for patients requiring parenteral administration or those who fail naloxegol.